A Capsida scientist at work in the company’s laboratory in Thousand Oaks. (courtesy photo) Many companies will be facing familiar and tough challenges in 2022 as year three of the COVID-19 pandemic begins. Capsida Biotherapeutics, a venture-backed biotechnology startup in Thousand Oaks, will be doing so with a new leader at the helm. Peter Anastasiou,…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
